Molecular Residual Disease Interception in Locoregionally-Advanced High Risk HPV+ and HPV- HNSCC

PHASE2RecruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

July 12, 2023

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2026

Conditions
Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC)
Interventions
BIOLOGICAL

AZD2936

AZD2936 is a monovalent, bispecific, humanized, IgG1 triple mutant mAb antibody against human PD 1 and TIGIT. AZD2936 was constructed on the backbone of the DuetMab molecule (Mazor et al., 2015), and its antigen binding fragment portions are comprised of the variable domains of the anti TIGIT COM902 antibody and anti PD 1 LO115 antibody. The IgG1 Fc domain carries the triple mutation (L234F/L235E/P331S) designed to reduce Fc mediated immune effector functions. In the preclinical studies, dual blockade of TIGIT and PD 1 by AZD2936 enhanced human T cell function and promoted antitumor immune responses.

Trial Locations (1)

Unknown

RECRUITING

Princess Margaret Cancer Centre, Toronto

All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

collaborator

NeoGenomics Laboratories, Inc.

UNKNOWN

lead

University Health Network, Toronto

OTHER